Summary:
The purpose of this study is to evaluate the efficacy of sirukumab as adjunctive treatment to antidepressant therapy. The study may take up to 12 weeks.
Qualified Participants Must:
• Be between 21 and 64 years of age (Adult)
•
Be diagnosed with MDD
Qualified Participants May Receive:
Study-related medical care and investigational drug at no cost and may be compensated for time and travel.